College of Pharmacy, University of Arizona, 1703 East Mabel, Tucson, Arizona, USA.
AAPS PharmSciTech. 2010 Mar;11(1):247-52. doi: 10.1208/s12249-010-9383-2. Epub 2010 Feb 12.
In vivo, the DNA methyltransferase inhibitor, 5-fluoro-2'-deoxycytidine (FdCyd, NSC-48006), is rapidly converted to its unwanted metabolites. Tetrahydrouridine (THU, NSC-112907), a cytidine deaminase inhibitor can block the first metabolic step in FdCyd catabolism. Clinical studies have shown that co-administration with THU can inhibit the metabolism of FdCyd. The National Cancer Institute is particularly interested in a 1:5 FdCyd/THU formulation. The purpose of this study was to investigate the in vitro pH stability of FdCyd and THU individually and in combination. A stability-indicating high-performance liquid chromatography method for the quantification of both compounds and their degradants was developed using a ZIC(R)-HILIC column. The effect of THU and FdCyd on the in vitro degradation of each other was studied as a function of pH from 1.0 to 7.4 in aqueous solutions at 37 degrees C. The degradation of FdCyd appears to be first-order and acid-catalyzed. THU equilibrates with at least one of its degradants. The combination of FdCyd and THU in solution does not affect the stability of either compound. The stability and compatibility of FdCyd and THU in the solid state at increased relative humidity and at various temperatures are also evaluated.
在体内,DNA 甲基转移酶抑制剂 5-氟-2'-脱氧胞苷(FdCyd,NSC-48006)会迅速转化为不需要的代谢物。胞苷脱氨酶抑制剂四氢尿苷(THU,NSC-112907)可以阻断 FdCyd 代谢的第一步。临床研究表明,与 THU 联合使用可以抑制 FdCyd 的代谢。美国国家癌症研究所特别关注 FdCyd 与 THU 的 1:5 制剂。本研究旨在单独和联合研究 FdCyd 和 THU 的体外 pH 稳定性。开发了一种使用 ZIC(R)-HILIC 柱的稳定性指示高效液相色谱法,用于定量两种化合物及其降解产物。研究了在 37°C 水溶液中 pH 值为 1.0 至 7.4 的条件下,THU 和 FdCyd 对彼此体外降解的影响。FdCyd 的降解似乎是一级和酸催化的。THU 与至少一种其降解产物达到平衡。在溶液中,FdCyd 和 THU 的组合不会影响任何一种化合物的稳定性。还评估了 FdCyd 和 THU 在增加的相对湿度和各种温度下的固态的稳定性和相容性。